AI-Guided Support for Prostate Cancer Education

(COUNSEL Trial)

This trial tests an AI tool to determine if it can help people better understand prostate cancer information after meeting with their cancer doctor. The study compares two groups: one using AI with a large language model (a type of smart computer program) and one without it. Those newly diagnosed with localized prostate cancer who have just had or plan to have a consultation about treatment options at UCSF may be a good fit. Participants must be able to join online meetings and speak English. The trial aims to determine if the AI-guided COUNSEL Intervention helps patients feel more informed about their condition and treatment.

As an unphased trial, this study offers a unique opportunity to contribute to innovative research that could enhance patient understanding and decision-making in prostate cancer care.

Research has shown that AI tools, like the one under study, are generally safe for use in medical settings. For example, one study found that AI can educate and support cancer patients without causing harm. Another study found that AI in healthcare often avoids providing incorrect information but might omit important details. This suggests that while the AI itself doesn't directly cause harm, users should be aware of potential information gaps.

Unlike the standard of care for prostate cancer education, which often involves traditional patient-physician consultations and printed materials, the AI-guided COUNSEL intervention is unique because it employs advanced AI teleconferences featuring interaction with a Large Language Model (LLM). This approach allows for personalized and dynamic patient education, adapting in real-time to individual patient needs and questions. Researchers are excited about this trial because it could revolutionize patient education by providing tailored, interactive support that enhances understanding and engagement, potentially leading to better patient outcomes.

Research has shown that AI tools can help patients better understand prostate cancer. For instance, patients using an AI assistant felt more confident about their knowledge, with Health Confidence Scores rising from 9.9 to 13.9 on a 16-point scale. AI models also show promise in predicting treatment effectiveness, aiding patients in making informed decisions. Additionally, AI chatbots have been developed to educate patients about prostate diseases, tests, and treatment options. In this trial, participants in the Intervention Arm will receive the AI-guided COUNSEL Intervention, which includes AI teleconferences with Large Language Model (LLM) interaction. Overall, these early findings suggest that AI tools like the AI-guided COUNSEL Intervention could significantly enhance patient education and understanding.⁶⁷⁸⁹¹⁰